Cytovance Biologics Inc.' Jesse McCool, Ph.D., To Present At 2015 BioInnovation Summit In London, UK

OKLAHOMA CITY, OK--(Marketwired - January 20, 2015) -

Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing company is gearing up for The BioInnovation Summit in London, UK February 10-11, 2015. Jesse McCool, Ph.D., will present on one of Cytovance's open innovation projects, the Keystone Expression System™. "Our Strategic Projects team at Cytovance is responsible for fostering open innovation across Cytovance with a mission of capturing and cultivating good ideas, developing new capabilities and corporate alliances and expanding Cytovances' service offerings," commented Darren Head, President and CEO. He added that "our business and customer values drive us to focus on the task at hand. Managing innovation projects becomes a matter of constant review and re-prioritization to achieve our external and internal goals."

The Keystone Expression System™ is an E. coli expression platform featuring a toolbox approach to gene design, host construction, and clone screening evaluation. The platform uses a Quality-by-Design (QbD) approach to achieve processing goals and GMP facility fit. To hear more of Dr. McCool's presentation and other exciting innovations in the Biomanufacturing space, please join us at GBX in London, February 10-11.

The presenter, Jesse McCool, Ph.D., is the Senior Vice President of R&D Services. Prior to joining Cytovance in 2013, Jesse served as Director of Process Development at LONZA, responsible for microbial Strain Development and Downstream Process Development functions. As an established speaker, he has chaired and presented at various industry conferences including Recent Advances in Fermentation Technology, Society for Industrial Microbiology and Biotechnology, Biotechnology Industry Organization, and International Society for Pharmaceutical Engineering.

Cheryl Tuck
Marketing Communications Manager

Help employers find you! Check out all the jobs and post your resume.

Back to news